OmniAb, Inc. (OABI) Earnings Call Transcript & Summary

March 18, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 49 min

Earnings Call Speaker Segments

Kurt Gustafson

executive
#1

Thanks, operator, and good afternoon to all of you. I'm Kurt Gustafson, serving as OmniAb's Chief Financial Officer, and I appreciate you being here for our conference call covering financial results for the fourth quarter and the full year 2024. Slides have been prepared to go along with today's prepared remarks, and you can find them in the Investors section on our website, www.omniab.com. Before getting started, please allow me to remind those listening that remarks management makes on this call will contain forward-looking statements as defined under federal securities laws. Such forward-looking statements carry risks and uncertainties that might lead actual results to differ materially from any results anticipated; these forward-looking statements are limited by the cautionary statements included in today's press release as well as our SEC filings. Importantly, time-sensitive information is contained in this conference call, and it is accurate only as of the date of this live broadcast, which is today, March 18, 2025. Unless the law requires otherwise, OmniAb assumes no obligation to revise or update any forward-looking statements so they reflect events or circumstances occurring after the date of this call. With me on the call today is OmniAb's President and CEO. On today's call, Matt and I will walk through highlights regarding the company's operations, updates on partners and technology, and our recent financial results. Once the prepared remarks are finished, we'll open the call for questions; and with that, I'll hand the call over to Matt.

Matt Foehr

executive
#2

Thanks, Kurt. Good afternoon, everyone, and we appreciate you being here today. Beginning on Slide 4, I'm happy to share that 2024 brought robust results and momentum, with double digit percentage increases in both active partners and active programs using our technology. The clinical stage programs belonging to our partners continue to move forward, and their progress has us encouraged. We've launched new technologies and improvements that are benefiting our partnerships and generating efficiencies across our increasingly scalable business; these innovations set us apart in the market while also drawing in new partners and opening the door to substantial growth potential ahead. We're starting to get a clearer picture of which royalty assets could really matter, plus the other pieces that add value and should fuel our growth over the next few years. Looking forward into 2025, the opportunities in front of us have us excited, and we feel good about what we've planned. On slide 5, this diagram gives you something of a sketch, plus some specifics, about the way we see our business and how someone might think about the connected pieces of value at OmniAb. Let's begin at the top left: our platform technologies remain novel, which keeps setting us apart, brings in fresh partnerships, and pushes partners we already have to launch additional programs. Our partnerships keep expanding, and the close ties we maintain with those companies give us an industry perspective few others have. That perspective shapes how we evaluate emerging tech developments and product rollouts, and it also guides our decisions on strategic tech acquisitions. By this point, we've built up quite a history in that regard. As the middle portion of the slide indicates, everything begins with what we add to the pipeline when it comes to generating value. There, we've achieved growth in the double digits across a span of several years, and we managed that amid all sorts of broader industry conditions. To me, that speaks to how durable our model is and how widely our technologies can be applied. When programs move forward into clinical development—shown at the upper part of the circle on the right-hand side of this slide—they typically begin gaining more public attention, and those programs tend to trigger the collection of milestone payments we've already contracted. Eventually, we anticipate that a number of these programs will mature into assets that generate royalties, which represents a fundamental source of value. Put simply, a royalty means a share of top-line revenue expressed as a percentage, and royalties are capable of producing reliable, long-lasting cash flow streams that grow as product sales rise. A given royalty asset's worth gets shaped by several things — who the partner is and how much they're putting in, what the program looks like as it turns into a product, and how big its commercial opportunity or total addressable market might be, which things like how many indications or how many geographies are being chased can affect. At different moments across a program's or product's lifecycle, any one of those pieces, or some mix of them, can create substantial value. As more programs advance, greater exposure across the industry keeps coming to our platform, along with more and more validation; in our view, that in turn powers additional pipeline growth. We remain deeply dedicated to our approach and concentrate on generating worth for every one of our stakeholders within this exceptionally leverageable operational structure. Let me now address several of our important business measurements, beginning on Slide 6 with active partners. We are happy to share that the count of active partners rose 18% compared with the prior year, reflecting our sustained push to broaden and diversify the partnerships we hold. On December 31st, 2024, our active partner total stood at 91; during Q4 we brought in new platform licenses with Incyte Corporation and Photinia Biosciences, while fresh commercial partners encompassed NBP Pharma and Taiho Pharma. As the pie charts in the call-out box indicate, the mix of our partners covers academia, commercial, and discovery categories. You can also view a breakdown there, a geographic breakdown of our partners too. Our expanding partner roster mirrors strong sector appetite for our technologies and likewise amounts to an acknowledgment of how devoted we are to innovation and working collaboratively. Across recent years, we have delivered consistent expansion in active partners through multiple cycles within biotech and pharma. Switching to Slide 7 now. We likewise experienced strong year-over-year expansion in active program count, up 12%. As of December 31st, active programs, net of attrition, climbed to 362. Our fourth quarter proved especially productive when it came to additions. Last year, as we saw and as the wider industry has described, some pharmaceutical companies made deliberate changes to their therapeutic programs and pipelines, shifting priorities. Those kinds of adjustments are frequently driven by a desire to concentrate on research areas with greater impact, as well as to respond to evolving market demands and regulatory circumstances, yet they usually involve attrition as a built-in part of the drug development process. The bar graph we called out shows that in 2024 there were 31 cancellations and 69 programs actively added. In my view, it is truly important to note that more than 98% of the programs we have active come with contracted future economics owed to us, which means we are strongly positioned to create future value for our shareholders. Now on Slide 8, as of December 31, active clinical programs and approved products from partners totaled 32. Our partners have by now launched or finished beyond 200 distinct human clinical trials involving OmniAb-derived programs, signaling their considerable commitment and belief regarding those programs; such trials cover a variety of therapeutic areas, among them oncology, immunology, and other indications. This broad downstream clinical engagement underscores the reliance and the assurance our partners place in the novel therapeutics emerging from our plasma. During 2024, five OmniAb-derived programs reached the clinic; in Q4, a fresh J&J program aimed at GPRC5D plus INNOLAKE Pharma's anti-CD40 agonist program each began Phase 1 clinical trials. Based on what we've heard from our partners, we expect somewhere in the range of five to seven new clinical development entries for novel programs utilizing OmniAb technology in 2025. During 2024, as I mentioned earlier, five novel programs based on OmniAb advanced into the clinic. The top part of slide 9 shows these newly added clinical efforts, spanning programs with TEVA, Merck KGaA, GenMab, J&J, and Innolake. There were also five programs that exited clinical development last year, as the bottom section of this slide indicates, meaning the number of active clinical programs showed no net change from the previous year. On the clinical attrition side, two of those cases came from GenMab — both were pulled from clinical development in Q3 and Q4, but according to what the companies have made public, they're still running at earlier stages. As for the Roche and Amgen programs, which were reported in Q1 and Q4 of last year, those are no longer active. That said, they have little to no impact on what our partnered portfolio is worth, because we don't have any economics left in them. More generally, while the loss of certain programs shows just how much flux there is in drug development, new clinical entrants coming in highlight the ongoing innovation and the potential of our technology when it comes to identifying new therapeutic options.

Matt Foehr

executive
#3

So taken as a whole, these things kind of bring into focus both what's difficult and what's promising when it comes to discovering and developing therapeutics. On Slide 10, you can see how our portfolio of post-discovery stage assets has grown year over year. And I'll note that we're enthusiastic about the variety and the possible therapeutic impact of the assets sitting in our pre-clinical stage bucket, which is represented by the orange portion of that pie chart. We're hoping that in the quarters ahead, we'll be able to reveal more details about what specifically is in that orange portion and the programs it contains. Now, on Slide 11, what you'll see is what we're referring to as our prior format for displaying clinical stage and later partnered pipeline programs. As time has gone on, this pipeline has become somewhat too large for that traditional format. Recognizing where we could improve, we are now rolling out a new format for presenting our partnered clinical pipeline. That new format appears here on Slide 12, and it gives an overview of clinical and commercial programs arranged from Phase 1 all the way through to late stages in approvals, shown from left to right. Where a program is placed depends on its most advanced clinical status, and only programs in which OmniAb holds future or remaining economic interests are included in this layout. By including (ph) clinical and commercial stage partner programs that don't carry future remaining economic benefits for us, like Teclistamab or Tiragolumab, our goal is to direct attention toward financially impactful programs; we believe this layout will assist stakeholders in more rapidly synthesizing the value of our clinical and commercial stage pipeline; beyond that, it lets us easily call out new and additional indications and geographies that our partners are pursuing. We think that by presenting these elements clearly, we'll do a better job illustrating the unique value proposition behind each individual program. Now I'll just cover a handful of recent partner highlights. Some further updates from Q4 and recent months are covered in our press release that went out this afternoon, but I wanted to call attention to a few specific programs that stand out to us. Slide 13 covers Genmab's Acasunlimab, a bispecific antibody targeting PD-L1 and 4 to 1BB. Genmab recently — and I believe this was the first time — called attention to a potential billion-dollar market opportunity for Acasunlimab in non-small cell lung cancer, stressing the addressable patient populations across the US, Japan, and the EU; they are advancing through the final stages of clinical development for Acasunlimab and announced that a Phase 3 trial as a second-line therapy in non-small cell lung cancer is now enrolling patients. Genmab also anticipates giving an additional Phase 2 data update for Acasunlimab this year, and we'd potentially expect that at ASCO. On Slide 14, you can see that Teva has called attention to continued progress in their now more prominent innovative medicines pipeline and have been showcasing advancements with OmniRat-derived TEV-‘408 and OmniChicken derived TEV-’278. 408 is a potent anti-IL15 neutralizing antibody that's currently being developed for the treatment of celiac disease and vitiligo. Additionally, 278 is an anti-PD-1 IL-2 fusion protein that's in development for oncology. Now let's turn to Slide 15, which covers Immunovant's programs, IMVT-1402 and Batoclimab. Batoclimab is a promising anti-FcRn monoclonal antibody being used to treat autoimmune diseases. Meanwhile, IMVT-1402 is a next-generation anti-FcRn antibody engineered to achieve deep IgG reduction while keeping side effects to a minimum. In our view, these assets are positioned for significance, fueled by large total addressable markets spanning multiple indications. Immunovant characterizes IMVT-1402 as potentially best-in-class, pointing to its promising therapeutic potential. They recently laid out a number of near-term milestones and catalysts for both IMVT-1402 and Batoclimab. Right now they're enrolling patients in pivotal Phase 2b studies for Graves' disease and difficult-to-treat rheumatoid arthritis for IMVT-1402. They intend to kick off registrational programs for three additional indications by March 31st of this year, and their goal is to evaluate IMVT-1402 across a total of 10 indications by March 31st of next year. Regarding batoclimab, as you can see here, OmniAb (ph) anticipates multiple data readouts, with some coming in the very near future. At the start of this year, Evaluate Pharma published an industry report that featured a summary of their analysis of the 10 most valuable R&D programs on a net present value basis across the whole pharmaceutical industry. And we were pleased to see both Batoclimab and IMVT-1402 called out on that top 10 list. Now on Slide 16, as we look forward into 2025, we expect several catalysts to drive our continued growth and set the business up for success. Pipeline expansion and advancement stay key elements, with significant progress anticipated in clinical and future royalty programs. We're excited about the potential for new deals currently in progress and the launch of novel technologies that we believe should have a substantial impact on the industry, with more details on those launches to come during the year. We focused on and sought to further leverage our relationships and what we refer to as the OmniAb ecosystem of partners that we've built over the years. This lets us think about and analyze the economic returns for technology expansion and technology launch options that are available to us. And I believe the tech launch options we've invested in and are planning for this year can create significant opportunity and potential returns. And we're excited about that. Our partner bases keep growing and diversifying, providing a solid foundation for sustained expansion. And with a clear business model that's now positioned to be leveraged more efficiently, we think we're well equipped to create value for our stakeholders and achieve our strategic objectives; and with that, let me now turn the call back over to Kurt for a discussion of our fourth quarter financial results in our 2025 outlook. Kurt.

Kurt Gustafson

executive
#4

Thanks, Matt. I'll begin on slide 18, covering our fourth-quarter 2024 revenue. Total revenue climbed considerably, hitting $10.8 million, up from $4.8 million during the same stretch in 2023. The main driver behind this gain was stronger license and milestone revenue, which came from new deals along with clinical progress in our partners' programs. Service revenue fell off because we wrapped up work on several small molecule ion channel programs that were subsequently handed to the partner. On royalties, we generally get sales figures from partners after a delay, so we book royalty revenue using estimated net sales of our partners' products. Once the final sales figures arrive, whatever gap exists between our actual results and earlier estimates gets adjusted during the period when that becomes known. During the fourth quarter, we got an update containing some information about 2024 sales of Sugemalimab and Zimberelimab in China, and we reflected that downward adjustment in the fourth quarter to capture this new information. Now onto Slide 19, where we examine our operating expense. Operating expense for the fourth quarter would have come in below the prior year period were it not for a $2.7 million impairment charge tied to certain small molecule ion channel and tangible asset. That impairment charge stemmed from a change in where we focus for ion channels, moving from small molecules toward antibodies. This change led to impairment of certain small molecule related and tangible assets. As for R&D and G&A expense, each declined against prior year, largely because of lower stock-based compensation expense and reduced outside expenses, as we keep pushing efficiencies throughout our business; let's look at the quarterly P&L on slide 20 and concentrate on the bottom part of the P&L. Our net loss for the fourth quarter of 2024 came to $13.1 million, or $0.12 a share, against a net loss of $14.1 million, or $0.14 per share, in the prior year period. So moving along to Slide 21, you can see that for the full year, total revenue rose when you exclude the $10 million milestone tied to the first commercial sale to teclistamab in EU; that was recorded last year. The rise in license and milestone revenue, once you exclude this $10 million, was driven by progress in our partners clinical programs and new licensing deals. Service revenue dipped slightly year over year mainly because certain ion channel programs wrapped up, which was slightly offset by a rise in our service revenue for our antibody discovery work. On top of that, royalty revenue sits below the prior year, mainly because of the highly competitive PD-1, PD-L1 market dynamics in China, which caused lower product sales. Heading to Slide 22, full year operating expense was lower in 2024 compared with 2023. When it comes to R&D spending, we held steady, whereas G&A costs went down. That drop was driven primarily by consulting and service expenses in 2023 that didn't repeat, tied to our spin out as a public company, plus reduced legal costs and stock-based compensation. I'd also like to flag that impairment charges for the year totaled $3.8 million. Now let's go to Slide 23, and if we look at the P&L for the full year, again concentrating on the lower portion of that schedule, we posted a net loss of $62 million for 2024, which comes to $0.61 per share, versus a net loss of $50.6 million, or $0.51 per share, in 2023. Over on Slide 24, breaking the year down quarter by quarter, a few observations stand out. To begin with, just as we'd guided earlier, revenue came in heavier during the back half of the year. You'll likewise observe a broader pattern of declining R&D costs and declining G&A costs as time went on. And as I'll get into shortly, we anticipate that pattern carrying forward into 2025. Regarding amortization of intangibles, that line tends to be pretty consistent, though we recorded a pair of impairments — one during the second quarter and another during the fourth quarter — which pushed those two quarters away from their normal baseline. If we move to Slide 25, you can see our balance sheets covering both 2024 and 2023. The company maintains a strong capital position, and we closed out 2024 with $59.4 million in cash, landing at the upper end of the guidance range we'd given on our prior earnings call. As we noted on our Q3 earnings call back in November, we brought in $11.4 million of net proceeds through the ATM. The bulk of that came during the third quarter, with some portion falling in the fourth quarter; we haven't raised anything further under the ATM program past what we disclosed at that point. There's one more balance sheet item I want to highlight, since it ties into some of the guidance we're rolling out today. The third line in the liabilities section is deferred revenue. The majority of it was recorded on the balance sheet quite a few years back, before OmniAb spun off to become a standalone company, from upfront payments we received for the small molecule ion channel licenses. As we finish up work on those programs, we recognize the revenue and the deferred revenue balance shrinks as it amortizes across the research terms of those projects. You'll see that this balance has now come down to only $2.5 million. As a last item, let's look at Slide 26, where we're introducing our financial guidance for 2025. This marks the first occasion we've ever given revenue guidance. That guidance reflects information our partners have shared with us, along with details our partners have made public regarding their programs. Taking all of that into account, our outlook for 2025 revenue falls somewhere between $20 million and $25 million. That said, please look at the lighter shaded portions of the bars in the graph on the left. You'll see that a meaningful share of 2024's revenue was non-cash. In fact, nearly one-third of what we brought in last year never turned into cash actually collected during that period. A large chunk of our service revenue came from amortization of deferred service revenue, which I referred to a moment ago. One of the main reasons revenue drops in 2025 is that this non-cash part of service revenue is shrinking. And actually, on a cash basis, we do anticipate receiving more cash from our partners in 2025 than what came in during 2024. So even though revenue is going down, the decline is entirely attributable to the non-cash component. Turning to operating expense, I brought up the strategic shift in our ion channel business toward antibodies. That shift additionally brought our specific staffing needs into alignment with the volume and nature of the work being done in this area, and it led to a cut in ion channel related headcount earlier this quarter. Although this produced some charges in the first quarter, we continue to anticipate that our operating expense for the year will be lower in 2025 than in 2024. To be more precise, total operating expense should land between $90 million and $95 million. I'd also like to highlight that, historically, roughly 40% of our operating expense has been non-cash, mostly from amortization of intangibles and stock-based compensation, and we anticipate 2025 will look similar. Regarding our cash use, we anticipate that cash use in 2025 will be less than in 2024, not counting the proceeds from our 2024 ATM issuance. For reference, our cash use in 2024 came to $38.9 million once you remove the $11.4 million of proceeds from the ATM. One more remark on our tax rate. Although our tax rate could move around from quarter to quarter, we anticipate the full year effective tax rate in 2025 will be approximately 0%. That's because our valuation allowance should largely offset the tax benefit tied to our net loss. This tax benefit will ultimately be realized once the company reaches profitability. While the biotech industry is definitely experiencing some volatility, our business has kept performing well. The leadership here at OmniAb have operated businesses for many years and are committed to growing the business while simultaneously remaining fiscally responsible to position us for continued success. With that, I'll open up the call for questions. Operator.

Joe Pantginis

analyst
#5

Hi, everyone. Afternoon. I appreciate you answering our questions. If you have time, I have a few. To start, Matt, on the topic of attrition rates — clearly that's a routine feature of developing drugs in biotech. I'm wondering whether I'd be right to think most of it stems from clinical development decisions, first of all. But could some of those attrition figures come from technical problems?

Kurt Gustafson

executive
#6

Yes, thank you, Joe. No, I wouldn't say attrition has anything to do with technical problems. Regarding this, the attrition from last year — throughout the year we discussed large pharma pipeline realignment, and that got a lot of coverage during the year. I believe many shifts in the big pharma landscape have pushed lots of the big pharmas toward concentrating on work where differentiation is genuinely possible, and sometimes even toward pursuing larger ambitions in CNS and similar fields. That, I think, prompted certain big pharmas to adjust their clinical pipelines; apart from that, the remaining attrition that showed up, I'd call it the ordinary kind of attrition typical across the different phases of drug development. Notably, Q4 was a very strong quarter for us when it came to additions, And I believe that leaves us well positioned for this year. So overall that was encouraging to see.

Joe Pantginis

analyst
#7

No, that is quite useful. And I simply wanted to ask something. In the remarks you prepared, plus on your slide deck, you offered a small hint about new technology releases coming this year. So I'm curious — any additional details you're able to provide, and does that originate from platforms you already have, or is it more along the lines of completely fresh tech introductions?

Kurt Gustafson

executive
#8

Yes, excellent, excellent question, Joe. Thank you. What I'd say is, our dedication to innovation strikes us as a truly meaningful competitive edge. For one — we've observed that across the years, and we hear the same thing from partners whenever we speak with them; plus we've been putting money into innovation energetically throughout the past several years, and the investments we've completed are shaped by genuinely deep ties with our partners. That assists us in forming our thinking on both, and likewise shapes our technical and business confidence regarding emerging technologies and workflow improvements that we regard as innovation capable of genuinely creating value; over the past several years, we brought out OmnidAb, an engineered chicken containing a human framework, aimed at finding novel single domain antibodies. That has drawn in a substantial number of fresh partners; it's producing some pleasant expansion in our active programs. And it's additionally broadening, to a considerable degree, the therapy areas our partners are pursuing, into CNS and radiopharma and additional fields. Yet when we consider innovation, I'd also count items such as OmniDeep, which we also introduced during recent years, which is that collection of in silico tools, AI and machine learning components threaded across our tech platform, while also fueling new programs and generating new opportunities. And following that, we rolled out OmniHub toward the close of last year, a platform for bioinformatics tools that improve our workflows for partners, and the response to OmniHub has frankly been tremendous. So, as a rather lengthy way of getting to your question, this year we're genuinely thrilled about the new technologies we intend to bring out. My view is they can affect our partner ecosystem and the industry at large; and I'll simply note broadly that everything we're launching this year fits squarely within our strategy and the themes previously discussed, in that they'll make it possible to discover high-quality candidates faster and with greater efficiency; they scale easily, extend our current partnerships, and I believe will draw new partners too, and will keep setting us apart. So the sole additional detail I suppose I'll offer — typically we've introduced new items around major scientific conferences, and that approach has served us well. That usually means the PEGS Protein Engineering Conference in May in Boston, along with the AEC (ph) conference, which falls very late in the year down in San Diego. So those are just a few broad details. I hope that's useful.

Joe Pantginis

analyst
#9

No, it really does. And I suppose one more fast one — this may sound a bit self-deprecating — the easy reply would be yes, no, or it doesn't matter. Given the turbulent conditions Kurt mentioned and that all of us are aware of, do you believe there is any kind of drive toward more pipeline and development, where partners might put more cash to work?

Matt Foehr

executive
#10

Well, Joe, when we examine our company and the measures we follow, this is an operation that has proven resilient and performed strongly across many cycles. There are likely plenty of explanations for that. The technologies and the requirements they address, the various cycles — sub-cycles, even — that show up in our sector tied to therapeutic areas or research methods, be it internalization or externalization, and so forth. What's fortunate regarding our platforms is their scalability; they can be applied adaptively in many different ways. So it seems to me we're fairly well situated no matter what the environment looks like. Kurt, is there anything you would like to add?

Kurt Gustafson

executive
#11

That's right.

Joe Pantginis

analyst
#12

Great. I appreciate you all putting up with everything I've asked.

Matt Foehr

executive
#13

Of course, Joe — thank you.

Analyst

analyst
#14

Hey, everyone. Appreciate you taking the questions. So, to start with the first one — Kurt, could you give us some clarity around that $20 million to $25 million guidance? I'm just wondering, does that figure include both cash and non-cash items, or is it entirely cash? And if you wouldn't mind expanding a bit — you laid out several programs — is there any upside you've factored in from those? I realize it's never easy to pin down how much comes from collaboration revenue as opposed to license revenue, but some context would help, since this is the first time you're giving this guidance.

Kurt Gustafson

executive
#15

Sure, Puneeth. So that $20 million to $25 million figure is on a GAAP basis. We're attempting to make a gap-to-gap comparison. What I was hoping to highlight is, if you consider the reason the 2025 figure declines compared with 2024 — a significant portion of 2024 came from service revenue, correct? $6 million of it was amortization of service revenue, which is non-cash. That's the component that's disappearing. I sort of directed you toward the balance sheet. Look at deferred revenue there — the year-end balance is just $2.5 million. So we recognized $6 million of deferred revenue in the prior year. Only $2.5 million remains on the balance sheet to be recognized; so that's among the major items that's declining, and it's non-cash in any case. So I was simply attempting to offer some color around that, but to be specific, the $20 million to $25 million (ph) is a GAAP figure in terms of what we'd anticipate reporting. You raised the question of differentiation — at this stage, I don't believe we're separating out, within that revenue, milestones versus service revenue versus royalties, but you could infer, or you could, from what I've said, understand that the deferred service revenue is a component that's definitely decreasing next year given the remarks I've made.

Analyst

analyst
#16

Understood, that helps. Then, academic work is a smaller portion of what your partners bring in, I realize, but I'm curious whether any effect is showing up there — clearly the markets are volatile, though even more significant, you know, there's just a great deal of NIH anxiety and such; so I'm just asking whether you're noticing any drop-off there.

Matt Foehr

executive
#17

Yeah, yeah, Puneet, it's Matt here. I appreciate the question. Obviously, when it comes to NIH funding, there's clearly been a lot of extensive coverage regarding how shifts in that area could or may affect academic research presently and going forward. As of now, that hasn't been affecting the way our network of academic collaborators works alongside us, but we are, you know, keeping an eye on that situation, and we're in active conversation with prospective academic partners right now, and those talks have moved forward in spite of the headlines and, well, the shifting character of the environment, and you know, I recognize all of that — we'll share, you know, our figures, fresh partnerships for this year when we report Q1 in May, but we actually just brought a new top-tier academic institution into a new agreement within the past week or so, with an organization that's quite keen on using our OmnidAb technology across a number of rather impactful fields. So that was encouraging to witness. But we'll keep monitoring the space.

Analyst

analyst
#18

Understood. Then I have one additional question. You mentioned that Q4 was particularly strong when it came to additions. Has that carried over to Q1, and now into March? Thanks.

Matt Foehr

executive
#19

Yes, I believe, regarding part of that, when it comes to the work we're actively beginning, I'd say broadly, yes. We do receive reports on other parts of our technology that arrive afterward. So it's difficult to state precisely. I'm not sure, Kurt, do you have anything?

Kurt Gustafson

executive
#20

Yeah, I think, Puneet, when it comes to something like milestone revenue, right? It can be uneven across quarters. And with this particular data, it really depends on when partners send us reports about what they're working on. A number of these, you know, companies only give us numbers quarterly; in a few cases, they do it just once a year. So don't read too much into any one quarter regarding what's going on there. Obviously, the overall direction across the year is quite strong and we expect that to keep going, but I'm not sure I'd take a ruler and start drawing lines from what Q4 looked like.

Analyst

analyst
#21

That's helpful, okay, all right, thank you.

Analyst

analyst
#22

Good afternoon. Appreciate you taking the questions. Maybe to start, and I just want to confirm I was reading the slides the right way. So I believe you expect 5 to 7 new clinical entrants in this year. My assumption would be that most, if not all of those, would set off milestones. And then 1 of the slides indicates you now have 4 in Phase 3. As we look ahead, and I'm not requesting guidance, but as we look ahead to 2026, 2027, it would seem that you — I mean, as those sort of make their way through the clinic, there's a chance to see a good step up not only in milestones upon approval, if that occurs, but also in royalties, am I thinking about that the right way?

Matt Foehr

executive
#23

Yeah, Matt, I can weigh in, and I'm sure Kurt will have something to say just on the overall metrics you're referring to; obviously we've presented a new view of our pipeline chart, right, to really concentrate only on the programs that carry downstream economics. And to answer your question broadly, broadly, when a program begins a clinical trial, that will set off a milestone in some fashion; and I phrase it that way because each contract — I mean, there can be variations across a range of contracts. She looks across every one of our programs. More than 98% of them have downstream economics to us, right? So that's, I think, a key thing to remember. There are programs now that we've sort of taken out of our pipeline visual representation, but for historical comparative reasons are in our overall metrics. A number of those are at later stages of development. Again, deals that were struck a long time ago that we inherited. But yeah, hopefully that responds to your question on milestones.

Analyst

analyst
#24

That answers it. Moving on to something else, it seems you've gotten a lot of encouraging responses regarding OmniHub. From what I recall, during the prior quarter you mentioned finishing what amounted to a beta trial, or beta test, alongside a partner, after which data was to be shared in December. So at this point, are customers or partners being enrolled or signed up for that offering, and if that's the case, how ought we to view its ramp across the year? Thank you.

Kurt Gustafson

executive
#25

Yes, thank you Matt. So indeed, partners are making use of OmniHub right now. During our prior call, I believe that was in November, we brought up the fact that data work had already been carried out alongside early adopters, so to speak. That said, OmniHub was introduced by us in December at the AET conference held down in San Diego. And the response, along with the feedback, has been excellent regarding it. Through a digital format, it lets us share data along with tools and similar items with our partners, and represents a fairly organic progression and extension of our technologies as we, you know, first, begin sharing additional data with additional partners, and have rolled out items such as OmniDeep, our in silico tool suite woven across our platform. OmniHub represented an organic technological growth for us, one we introduced in December, and it has gone extremely well.

Analyst

analyst
#26

That's great, thank you.

Kripa Devarakonda

analyst
#27

Hey everyone, thanks a lot for taking my questions, and congratulations on all the progress. Regarding those 2 licenses — with Incyte and Photinia, I believe — that you disclosed in Q4, could you share any further detail, whether about therapeutic areas, the indications, or possibly the platforms they'd be using? And when it comes to therapeutic areas, you'd said before that OmnidAb unlocks far more possibilities, and you specifically brought up neuroscience along with oncology. Could you speak to whether that pattern is holding, whether it's broadened, or whether any shifts have occurred there? Thank you.

Matt Foehr

executive
#28

Yeah, Kripa, thanks; regarding how therapy areas are evolving, OmnidAb, you know, we introduced it back in November of 2023, and it has definitely driven a rise in the number of partners who are interested in CNS targets and are going after them — what I'd call high-value CNS targets; we also certainly have partners who use OmnidAb with an emphasis on oncology, in multi-specifics, and in areas of that kind, yet it has definitely broadened the variety within our discovery pipeline by adding CNS. We're seeing genuine interest in radiopharma too. When it comes to both Incyte and Photinia, I'm not able to say much about which areas interest them with respect to our platforms, except that they hold broad platform access, which lets them reach multiple species, our proprietary screening technologies, and other downstream technologies and workflows. So that's all I have for you on that.

Kripa Devarakonda

analyst
#29

All right, that's excellent. Many thanks.

Analyst

analyst
#30

Hello everyone, Tolion (ph) here on behalf of Steve, and I appreciate you fielding this. To kick things off, I'd like to ask about the preclinical discovery work you're doing. Looking at those 5 incremental programs, or the 20 total in preclinical, does one specific platform show up more than the rest? Put differently, I'm attempting to figure out whether a certain platform is drawing greater partner interest. That's my first one, and I'll follow up with another afterward.

Matt Foehr

executive
#31

Thanks very much, Leigh. Regarding the 20 programs sitting in the preclinical stage, broadly speaking I'd say the variety of therapeutic areas represented makes us quite happy — wide-ranging therapeutic interests, truly meaningful indications where substantial unmet medical need exists. Beyond that, there's a blend of our source technologies involved, including our OmniRodent (ph) technologies, our Bi-specific technologies, OmniFLIC and OmniCLIC, plus our chicken-based technologies too. So yes, it's a pleasant blend and diversity. Typically, once those programs reach the clinic, more details become available regarding the particular targets partners are chasing, the way they're handling their clinical development, and so on, and we anticipate being able to share more on that as the year goes on and programs move from preclinical into clinical.

Analyst

analyst
#32

All right. Thanks a lot. That's quite useful. My follow-up actually concerns one of the advanced assets — Sugemalimab, which you're working on together with CStone. Could you remind me how the downstream economics work for that asset? CStone seems to have been achieving meaningful momentum on the commercial front. The reason I'm raising this is I want to know whether a possible royalty payment is in fact included in the 2025 revenue guidance.

Matt Foehr

executive
#33

Sure, what I can say is that the royalty rate for Sugemalimab as well as Zimberelimab comes to 3% across the globe. That answers that. As for the guidance, I believe it captures revenue from milestones, service revenue, and royalties, though my sense is we lack much visibility into what sales will look like in those territories, so I doubt there's much upside from that sort of thing built into our guidance.

Analyst

analyst
#34

Thank you very much, and that's excellent.

Matt Foehr

executive
#35

Thanks, everyone, for being on today's call. We're grateful for the questions and the participation. We're eager to continue sharing news about how things are going and to talk with you again in the next quarter. Until then, once more, we're thankful for your interest in OmniAb, and enjoy the rest of your day.

Operator

operator
#36

Everyone, that wraps up the conference call for today. We appreciate you joining us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.